Intratumoral bacteria as potential contributor of gemcitabine resistance

Melanie S. Patzak, Volker Ellenrieder, Albrecht Neesse


Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a 5-year relative survival rate of about 8%. With increasing incidence and death rates pancreatic cancer is projected to become the second leading cause of cancer-related death in the U.S. by 2030 (1,2).